ALLERGIC RHINITIS TREATMENT MARKET ANALYSIS

Allergic Rhinitis Treatment Market, By Treatment Type (Immunotherapy (Sub-cutaneous Immunotherapy, Sub-lingual Immunotherapy), Anti-histamines, Decongestants, Leukotriene Receptor Antagonists, Corticosteroids, and Others), By Route of Administration (Oral, Nasal, Intraocular, and Others), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and E-commerce), By Geography (North America, Latin America, Europe, Asia Pacific, Middle East & Africa)

Published In : Apr 2024
Code : CMI1201
Pages :181
Formats :
Excel and PDF
Industry : Pharmaceutical

Market Challenges – Termination of The Clinical Trial Study

The major factors that are expected to hinder growth of the global allergic rhinitis treatment market include the termination of the clinical trial study. For instance, in November 2022, a clinical trial of Tree MATA MPL or Tree MATA immunotherapy for allergic rhinitis and type I hypersensitivity I was terminated due to poor enrollment of subjects. The clinical trial was sponsored by Allergy Therapeutics, a manufacturer of subcutaneous and sublingual immunotherapy treatments.

Market Opportunities – Increasing Launch of Awareness Campaigns

Increasing adoption of inorganic growth strategies such launch of awareness campaigns by key market players is expected to offer lucrative growth opportunities in the market. For instance, in June 2023, Alkem, a global pharmaceutical company, announced that they had launched "Stop Sneeze to Wheeze" Campaign to Raise Awareness on Allergic Rhinitis and Asthma Coexistence during World Allergy Week 2023. The programme highlights the idea of "One Airway, One Disease" and seeks to increase awareness of the coexistence of allergic rhinitis and asthma.